Literature DB >> 23165210

p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP.

Harsha S Madapura1, Daniel Salamon, Klas G Wiman, Sonia Lain, George Klein, Eva Klein, Noémi Nagy.   

Abstract

Lack of functional SAP protein, due to gene deletion or mutation, is the cause of X-linked lymphoproliferative disease (XLP), characterized by functionally impaired T and NK cells and a high risk of lymphoma development. We have demonstrated earlier that SAP has a pro-apoptotic function in T and B cells. Deficiency of this function might contribute to the pathogenesis of XLP. We have also shown that SAP is a target of p53 in B cell lines. In the present study, we show that activated primary T cells express p53, which induces SAP expression. p53 is functional as a transcription factor in activated T cells and induces the expression of p21, PUMA and MDM2. PARP cleavage in the late phase of activation indicates that T cells expressing high levels of SAP undergo apoptosis. Modifying p53 levels using Nutlin-3, which specifically dissociates the MDM2-p53 interaction, was sufficient to upregulate SAP expression, indicating that SAP is a target of p53 in T cells. We also demonstrated p53's role as a transcription factor for SAP in activated T cells by ChIP assays. Our result suggests that p53 contributes to T cell homeostasis through the induction of the pro-apoptotic SAP. A high level of SAP is necessary for the activation-induced cell death that is pivotal in termination of the T cell response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23165210      PMCID: PMC3562301          DOI: 10.4161/cc.22810

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  38 in total

1.  Mechanism-specific signatures for small-molecule p53 activators.

Authors:  Ingeborg M M van Leeuwen; Maureen Higgins; Johanna Campbell; Christopher J Brown; Anna R McCarthy; Lisa Pirrie; Nicholas J Westwood; Sonia Laín
Journal:  Cell Cycle       Date:  2011-05-15       Impact factor: 4.534

2.  Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription.

Authors:  T Kanaya; S Kyo; K Hamada; M Takakura; Y Kitagawa; H Harada; M Inoue
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Telomerase levels control the lifespan of human T lymphocytes.

Authors:  Alexander Roth; Hans Yssel; Jerome Pene; Elizabeth A Chavez; Mike Schertzer; Peter M Lansdorp; Hergen Spits; Rosalie M Luiten
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines.

Authors:  N Nagy; C Cerboni; K Mattsson; A Maeda; P Gogolák; J Sümegi; A Lányi; L Székely; E Carbone; G Klein; E Klein
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

5.  Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis.

Authors:  Rosalie M Luiten; Jérome Péne; Hans Yssel; Hergen Spits
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

6.  Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells.

Authors:  D Xu; Q Wang; A Gruber; M Björkholm; Z Chen; A Zaid; G Selivanova; C Peterson; K G Wiman; P Pisa
Journal:  Oncogene       Date:  2000-10-26       Impact factor: 9.867

Review 7.  Post-translational modification of p53 in tumorigenesis.

Authors:  Ann M Bode; Zigang Dong
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.

Authors:  Noémi Nagy; Akihiko Maeda; Kentaro Bandobashi; Loránd L Kis; Jun Nishikawa; Pankaj Trivedi; Alberto Faggioni; George Klein; Eva Klein
Journal:  Int J Cancer       Date:  2002-08-01       Impact factor: 7.396

9.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

10.  X-linked lymphoproliferative syndrome. An immunodeficiency disorder with acquired agammaglobulinemia, fatal infectious mononucleosis, or malignant lymphoma.

Authors:  D T Purtilo
Journal:  Arch Pathol Lab Med       Date:  1981-03       Impact factor: 5.534

View more
  11 in total

1.  cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response.

Authors:  Harsha S Madapura; Daniel Salamon; Klas G Wiman; Sonia Lain; Eva Klein; Noémi Nagy
Journal:  Cell Cycle       Date:  2016-05-02       Impact factor: 4.534

2.  T helper cell-mediated epitranscriptomic regulation via m6A RNA methylation bridges link between coronary artery disease and invasive ductal carcinoma.

Authors:  Sudeshna Rakshit; Jithin S Sunny; Melvin George; Luke Elizabeth Hanna; K V Leela; Koustav Sarkar
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-01       Impact factor: 4.322

3.  Somatic inactivation of Tp53 in hematopoietic stem cells or thymocytes predisposes mice to thymic lymphomas with clonal translocations.

Authors:  Amy DeMicco; Katherine Yang-Iott; Craig H Bassing
Journal:  Cell Cycle       Date:  2013-09-09       Impact factor: 4.534

4.  The volume-regulated anion channel LRRC8C suppresses T cell function by regulating cyclic dinucleotide transport and STING-p53 signaling.

Authors:  Axel R Concepcion; Larry E Wagner; Jingjie Zhu; Anthony Y Tao; Jun Yang; Alireza Khodadadi-Jamayran; Yin-Hu Wang; Menghan Liu; Rebecca E Rose; Drew R Jones; William A Coetzee; David I Yule; Stefan Feske
Journal:  Nat Immunol       Date:  2022-02-01       Impact factor: 31.250

5.  Molecular dynamics of the full-length p53 monomer.

Authors:  Giovanni Chillemi; Pavel Davidovich; Marco D'Abramo; Tazhir Mametnabiev; Alexander Vasilievich Garabadzhiu; Alessandro Desideri; Gerry Melino
Journal:  Cell Cycle       Date:  2013-09-05       Impact factor: 4.534

Review 6.  Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy.

Authors:  Yong Liu; Patrick L Leslie; Yanping Zhang
Journal:  Trends Cancer       Date:  2020-11-13

7.  Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.

Authors:  Balu Kamaraj; Annemie Bogaerts
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

8.  Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab.

Authors:  Maria Sole Chimenti; Paola Tucci; Eleonora Candi; Roberto Perricone; Gerry Melino; Anne E Willis
Journal:  Cell Cycle       Date:  2013-08-19       Impact factor: 4.534

Review 9.  Oncogenes in immune cells as potential therapeutic targets.

Authors:  Gulnur K Zakiryanova; Sarah Wheeler; Michael R Shurin
Journal:  Immunotargets Ther       Date:  2018-04-11

10.  Dysregulated TP53 Among PTSD Patients Leads to Downregulation of miRNA let-7a and Promotes an Inflammatory Th17 Phenotype.

Authors:  Philip B Busbee; Marpe Bam; Xiaoming Yang; Osama A Abdulla; Juhua Zhou; Jay Paul Jack Ginsberg; Allison E Aiello; Monica Uddin; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.